Диагностические критерии гепаторенального синдрома и современные методы терапии (обзор литературы)
https://doi.org/10.17650/2408-9613-2017-4-2-6-11
Аннотация
Об авторах
Р. Р. Нагимуллин
ФГБОУ ВО «Казанский государственный медицинский университет» МЗ РФ;
ГАУЗ «Городская клиническая больница № 7» МЗ РТ
Россия
Россия
Контактное лицо: Рамиль Раисович Нагимуллин
420012, г. Казань, ул. Бутлерова, д. 49.
Д. Ю. Устимов
ФГБОУ ВО «Казанский государственный медицинский университет» МЗ РФ;
ГАУЗ «Городская клиническая больница № 7» МЗ РТ
Россия
Россия
420012, г. Казань, ул. Бутлерова, д. 49
В. Р. Давыдова
ФГБОУ ВО «Казанский государственный медицинский университет» МЗ РФ
Россия
Россия
420012, г. Казань, ул. Бутлерова, д. 49
Ф. А. Шипулин
ФГБОУ ВО «Казанский государственный медицинский университет» МЗ РФ
Россия
Россия
420012, г. Казань, ул. Бутлерова, д. 49
Список литературы
1. Egerod Israelsen M. Acute kidney injury and hepatorenal syndrome in cirrhosis. J. Gastroenterol. Hepatol. 2015; 30(2): 236–243.
2. Lenz K. Treatment and management of ascites and hepatorenal syndrome: an update. Adv. Gastroenterol. 2015; 8(2): 83–100.
3. Epstein M. Hepatorenal syndrome. Therapy in nephrology and hypertension. Ed. by H.R. Brady, C.S. Wilcox/ A companion to Brenner and Rector`s The Kidney. Philadelphia, London, Toronto, Montreal, Sydney, Tokio: WB Saunders Company. 1999: 45–51.
4. Arroyo V., Bataller R. Historical notes on ascites in cirrhosis. In: Ascites and renal dysfunction in liver disease. Ed. by V. Arryo, P. Gines, J. Rodes et al. Oxford, London, Edingburgh, Boston, Melbourne: Blackwell Science. 1999: 3–13.
5. Bernardi M. Hepatorenal syndrome and ascites – questions and answers. Liver. 1999; 19(1): 15–75.
6. Butt A.K. Predicting hospital mortality in cirrhosis patients: comparison of Child-Pugh and acute physiology, age and chronic health evaluation (APACHE III) scoring systems. Am. J. Gastroenterol. 1998; 93: 2469–2475.
7. Mindikoglu A. L. New Developments in Hepatorenal Syndrome Clin Gastroenterol. Hepatol. 2018; 16(2): 162–177.
8. Battaller R. Hepatorenal Syndrome. Seminars in Liver Disease. 1997; 17: 233–247.
9. Gines P. Pathophysiology of renal dysfunction in cirrhosis. Digestion. 1998; 59(2): 11–15.
10. Martin P.-Y. Pathogenesis of water and sodium retention in cirrhosis. Kidney International. 1997; 51: 43–49.
11. Bataller R. Hepatorenal syndrome: Definition, pathophysiology, clinical features and management. Kidney International. 1998; 53: 47–53.
12. Koppel M. H. Transplantation of cadaveric kidneys from hepatorenal syndrome: Evidence for the functional nature of renal failure in advanced liver disease. N. Eng. J. Med. 1969; 280: 1367–1371.
13. Nadim M. K. Living donor liver transplantation for hepatorenal syndrome: to do or not to do? That is the question. Liver Transpl. 2012; 18(10): 1138–1139.
14. Eckardt K.-U. Renal failure in liver disease. ntensive Care Medicine. 1999; 25: 5–14.
15. Guevara M. More therapy for hepatorenal syndrome. Gastroenterology. 1999; 116: 1265– 1266.
16. Schrier R. W. et al. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988; 8: 1151–1157.
17. Lang F. et al. Hepatorenal reflex regulating kidney function. Hepatology. 1991; 14: 590– 594.
18. Berkowitz H. D. Significance of altered renin substrate in the hepatorenal syndrome. Surg. Forum. 1972; 23: 342–343.
19. Wong F. et al. The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. Gastroenterology. 1998; 115: 397– 405.
20. Laffi G. et al. Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. Gastroenterology. 1992; 103: 1017–1021.
21. Martin P.-Y. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N. Eng. J. Med. 1998; 339: 533–541.
22. Moncada S. et al. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Review. 1991; 43: 109–142.
23. Vallance P. Hyperdynamic circulation in cirrhosis: A role for nitric oxide. Lancet. 1991; 337: 776–778.
24. Saracyn M. et al. Effect of nitric oxide pathway regulation on water/sodium balance and renal function in a rodent model of acute liver and renal failure. Med. Sci. Monit. 2014; 27(20): 1735–1744.
25. Goligorsky M. S. Endothelin and renal dysfunction in liver disease. The kidney in liver disease. Ed. by M. Epstein. Philadelphia: Hanley & Belfus. 1996; 387–404.
26. Rebholz C. M. et al. Association between Endothelin-1 Levels and Kidney Disease among Blacks. J. Am. Soc. Nephrol. 2017; 28(11): 3337–3344.
27. Simonson M. S. Endothelins: multifunctional renal peptides. Physiol. Rev. 1993; 43: 375–411.
28. Petros A. et al. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991; 338: 1557–1558.
29. Suffredini A. F. et al. The cardiovascular response of normal humans to the administration of endotoxin. New England Journal of Medicine. 1989; 321: 280–287.
30. Ozkok A. Hepatitis C virus associated glomerulopathies. World J. Gastroenterol. 2014; 28; 20(24): 7544–7554.
31. Daugherty N. A. et al. Bilirubin interference with the kinetic Jaffe method for serum creatinine. Clin. Chem. 1978; 24: 392–393.
32. Halstead A. C. Artifactual lowering of serum creatinine in the presence of hyperbilirubinemia – a method depending artifact. JAMA. 1984; 251: 38–39.
33. Soldin S.J. et al. The effect of bilirubin and ketones on reaction rate methods for the measurement of creatinine. Clin. Biochem. 1978; 11: 82–85.
34. Celebi H. et al. Renal blood flow detection with Doppler ultrasonography in patients with hepatic cirrhosis. Arch. Int. Med. 1997; 157: 564–566.
35. Platt J. F. et al. Renal duplex Doppler ultrasonography: A noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology. 1994; 202: 362–369.
36. Guevara M. et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998; 27: 35–41.
37. Gülberg V. et al. Erfolgreiche konservative Therapie des hepatorenalen Syndroms mit dem Vasopressin-1-Rezeptoragonisten Ornipressin. Zeitschrift für Gastroenterologie. 1998; 36: 1053–1058.
38. Gülberg V. et al. Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine. Hepatology. 1999; 30: 870–875.
39. Ganne-Carrie N. et al. Hepatorenal syndrome. Long-term treatment with terlipressin as a brigde to liver transplantation. Dig. Dis. Sci. 1996; 41: 1054–056.
40. Angeli P. et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999; 29: 690–1697.
41. Holt S. et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999; 353: 294–295.
42. Sort P. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Eng. J. Med.1999; 341 (6): 403– 409.
43. Stefoni S. et al. Molecular adsorbent recirculating system (MARS) application in liver failure: clinical and hemodepurative results in 22 patients. Int. J. Artif. Organs. 2006; 29(2): 207–218.
44. Donati G. et al. Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up. Artif. Organs. 2014; 38(2): 125–134.
45. Platt J. F. et al. Renal duplex Doppler ultrasonography: A noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology. 1994; 202: 362– 369.
46. Epstein M. The LeVeen shunt for ascites and hepatorenal syndrome. N. Eng. J. Med. 1980; 302: 628–630.
47. Gerth H. U. et al. Molecular Adsorbent Recirculating System Can Reduce ShortTerm Mortality Among Patients With Acuteon-Chronic Liver Failure: A Retrospective Analysis. Crit. Care Med. 2017; 45(10): 1616–1624.
48. Ochs A. et al. The transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites. N. Eng. J. Med. 1995; 332: 1192–1197.
49. Rössle M. et al. The transjugular intrahepatic portosystemic stent-shunt procedere for variceal bleeding. N. Eng. J. Med. 1994; 330: 165–171.
50. Brensing K. A. et al. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet. 1997; 349: 697–698.
51. Guevara M. et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive system. Hepatology. 1998; 28: 416–422.
52. Somberg K. A. Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites and hepatorenal syndrome. The kidney in liver disease. Ed. by M. Epstein. Philadelphia: Hanley & Belfus. 1996: 507–516.
53. Spahr L. et al. Improvement of the hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. Am. J. Gastroenterology. 1994; 90: 1169–1171.
54. Готье С. В. Трансплантация печени: современное состояние проблемы. Альманах Института хирургии им. А.В. Вишневского. 2008; 3(83.8): 4–17.
Рецензия
Для цитирования:
Нагимуллин Р.Р., Устимов Д.Ю., Давыдова В.Р., Шипулин Ф.А. Диагностические критерии гепаторенального синдрома и современные методы терапии (обзор литературы). Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка. 2017;4(2):6-11. https://doi.org/10.17650/2408-9613-2017-4-2-6-11
For citation:
Nagimullin R.R., Ustimov D.Y., Davidova V.R., ShipuF. lin F.A. Diagnostic criteria of hepatorenal syndrome and modern methods of therapy (literature review). Wounds and wound infections. The prof. B.M. Kostyuchenok journal. 2017;4(2):6-11. (In Russ.) https://doi.org/10.17650/2408-9613-2017-4-2-6-11
Просмотров: 960
Послать статью по эл. почте 